ADCs and new modalities at EBF 2026

Nov 17–19, 2026 Barcelona, Spain ~800 attendees Website

10 organizations at EBF 2026 present work in adcs, oligonucleotides and other new modalities: 6 drug developers and 4 CROs and suppliers. Between them they bring 32 presentations to the program. Most represented: Roche (9 on the program), Charles River Laboratories (5 on the program), Sanofi (5 on the program). 7 of them have their own page in this guide. As of Oct 13, 2026.

All 63 organizations at EBF 2026 →

Showing 1–10 of 10 organizations

Organization	EBF 2026 Attendance
Roche Basel, Switzerland
roche.com Pharma Pharmaceutical and diagnostics group developing medicines in oncology, immunology, neuroscience and ophthalmology, alongside its Roche Diagnostics business.	Talk Tue Nov 17 11:30–11:50am Part of Session 2: Smarter Workflows: From Implementation to Scientific Confidence Clinical Speed meets GLP Rigor: Upgrading an IVD Immunoanalyzer for High-Throughput PK/PD Analysis in a Bioanalytical Laboratory - Lessons Learnt Automation & AI · Ligand binding Talk Tue Nov 17 2:40–3pm Part of Session 5: Expanding LC–MS Bioanalysis: New Modalities, Advanced Workflows and Multi-Omics LC-MS Bioanalysis of Lipid Conjugated siRNAs: Analytical Challenges and Novel Approaches New modalities · LC–MS Talk Tue Nov 17 5:20–5:40pm Part of Session 7: BM CoU in practice Navigating Soluble Biomarker Complexity: Challenges, Assay Strategy, and Case Studies Biomarkers Talk Wed Nov 18 9–9:20am Part of Session 10: Bioanalysis Beyond Conventional Matrices From First-in-Human to Multi-Site Trials: Practical Bioanalytical Strategies to Preserve CSF Pharmacokinetic Data for Highly Adsorptive Molecules Sampling Talk Wed Nov 18 9:20–9:40am Part of Session 12: Assay life cycle Assay Lifecycle in Practice: Strategic Stewardship, Change Control, and Revalidation Case Studies Regulation Talk Wed Nov 18 9:40–10am Part of Session 10: Bioanalysis Beyond Conventional Matrices Operationalizing Unstable Biomarkers: How Biosample Operations and Bioanalysis Enable Successful Scale-Up from Single-Site to Multi-Site Clinical Trials Biomarkers · Sampling Talk Wed Nov 18 5–5:20pm Part of Workshop 10: ADA - Adaptive Tier Overcoming the 3-Tier ADA Testing Paradigm via Mechanistic Assay Understanding Immunogenicity Talk Thu Nov 19 9:20–9:40am Part of Session 16: Protein MS tech 1 A Multiplexed LC-MS/MS Strategy for the Simultaneous Quantification of a Transgene Protein and its Endogenous Counterpart in a Gene Therapy Program. LC–MS Talk Thu Nov 19 11:30–11:50am Part of Session 20: Pushing the Limits of Sensitivity and Multiplexing in Bioanalysis Navigating High-Plex Profiling and Targeted Quantification in Drug Development Biomarkers
Charles River Laboratories Wilmington, Massachusetts	◇Sponsor
criver.com Bioanalytical CROsSponsor Contract research organization providing discovery, safety assessment and bioanalysis services for drug developers.	Talk Tue Nov 17 12:10–12:30pm Part of Session 3: Vaccines Harmonizing Validation of Vaccine Immunogenicity Assays: A Fit-for-Purpose Framework for Quantitative and Semi-Quantitative Methods Vaccines · Immunogenicity Talk Tue Nov 17 2:20–2:40pm Part of Session 4: Advancing the 3Rs: Smarter Sampling, Surrogate Matrices and Leaner Workflows Transition from Duplicate to Singlicate ADA Testing: A Retrospective Evaluation of Clinical Immunogenicity Data Immunogenicity · Sampling Talk Tue Nov 17 5–5:20pm Part of Session 8: Pharma CRO Analytical Challenges of Gas Shuttling Nanomedicine: A case study of Inter-CRO Transfer of a Bioanalytical Method for Complex Modalities New modalities Talk Wed Nov 18 12–12:20pm Part of Session 14: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 2 Rethinking In-Study Cut Point Application for siRNA Immunogenicity Assessment When False Positive Rates Fall Outside the Conventional Range Immunogenicity · New modalities Talk Thu Nov 19 12:10–12:30pm Part of Session 19: ADC Bioanalysis, From Community Recommendations to Complex PK Decisions Decoding ADC Complexity: Bioanalytical LC-MS Approaches and application to preclinical and clinical studies New modalities · LC–MS
Sanofi Paris, France
sanofi.com Pharma Pharmaceutical company developing medicines and vaccines in immunology, rare diseases, neurology and oncology.	Talk Wed Nov 18 12:10–12:30pm Part of Workshop 2: Emerging challenges in the e-environment Rethinking the Discovery Bioanalytical Dataflow using a Bespoke End-to-End Digital Solution Automation & AI Talk Wed Nov 18 12:20–12:40pm Part of Session 14: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 2 The Immunogenicity Nexus: Investigating the Predictive Relationship Between Early-Onset ADA Kinetics in NHP and Human Immune Responses Immunogenicity Talk Thu Nov 19 9–9:20am Part of Session 15: Flow From Raw Data to Insights in Minutes: Development of an Automated Flow Cytometry Data Pipeline for Preclinical Studies Cell-based · Automation & AI Talk Thu Nov 19 2–2:20pm Part of Session 21: Protein MS Tech 2 Generic Hybrid Immunocapture LC-MS/MS Approach for Integrity Assessment of Multispecific Antibodies in Clinical Studies: A Breakthrough Bioanalytical Strategy LC–MS · New modalities Talk Thu Nov 19 2:20–2:40pm Part of Session 21: Protein MS Tech 2 Advanced LC-MS Strategies for In Vivo Bioanalysis of Next-Generation Biotherapeutics: From Method Development to Multi-Therapeutic Area Applications LC–MS · New modalities
BioAgilytix Durham, North Carolina	◇Sponsor
bioagilytix.com Bioanalytical CROsSponsor Bioanalytical CRO specialising in large-molecule PK, immunogenicity, biomarker and cell-based assays, with labs in the US and Europe.	Talk Tue Nov 17 11:50am–12:10pm Part of Session 2: Smarter Workflows: From Implementation to Scientific Confidence Fit-for-Purpose Implementation of a Generic Preclinical PK Assay: Lessons from Platform Transfer and Troubleshooting Ligand binding Talk Tue Nov 17 5:40–6pm Part of Session 9: New technologies and emerging modalities in Bioanalysis: PCR Considering DNA & RNA Extraction for PCR-Based Assay Validations PCR Talk Wed Nov 18 12:20–12:40pm Part of Session 13: BioA Clinic Cross-Platform Evaluation of Total Antibody and Total ADC PK: LBA versus LC-MS New modalities · LC–MS Talk Thu Nov 19 11:10–11:30am Part of Session 20: Pushing the Limits of Sensitivity and Multiplexing in Bioanalysis Responding to Evolving Clinical Needs: A Collaborative Journey to an Ultra-Sensitive PK Assay Ligand binding
QPS Newark, Delaware	◇Sponsor
qps.com Bioanalytical CROsSponsor CRO specialising in regulated bioanalysis, DMPK, toxicology and clinical research.	Talk Tue Nov 17 2:20–2:40pm Part of Session 5: Expanding LC–MS Bioanalysis: New Modalities, Advanced Workflows and Multi-Omics M10 Compliant Quan–Qual Analysis of Parent Oligonucleotides and Metabolites Using a Next-Generation QTOF Platform New modalities · LC–MS Talk Tue Nov 17 5–5:20pm Part of Session 7: BM CoU in practice Best Practices of Performing Parallelism in Biomarker Assays: A CRO Perspective Biomarkers Talk Wed Nov 18 9:40–10am Part of Session 12: Assay life cycle Challenges during implementation of new reagent lots Ligand binding
Merck KGaA Darmstadt, Germany
merckgroup.com Pharma Science and technology group whose healthcare business develops medicines in oncology, neurology and fertility, alongside life science and electronics businesses.	Talk Wed Nov 18 10:20–10:40am Part of Session 11: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 1 Never Too Old to Be Questioned: What a 20-Year-Old Product Taught Us About Immunogenicity Expectations Immunogenicity Talk Thu Nov 19 11:50am–12:10pm Part of Session 19: ADC Bioanalysis, From Community Recommendations to Complex PK Decisions Hybrid Immunocapture (IC)/LC-MS methods for the simultaneous quantification of Total Antibody and Conjugated Payload across different species case studies. New modalities · LC–MS
Kymos	◇Sponsor
kymos.com Bioanalytical CROsSponsor Spanish CRO providing regulated bioanalysis, analytical development and quality-control testing for drug developers.	Talk Tue Nov 17 6–6:20pm Part of Session 9: New technologies and emerging modalities in Bioanalysis: PCR A Case Study in qPCR Bioanalysis of Viral vectors: Overcoming Matrix Effects and Extraction Challenges Using Automated Nucleic Acid Extraction PCR · New modalities
ADC Therapeutics Lausanne, Switzerland
adctherapeutics.com Biotech Develops antibody–drug conjugates for cancer, including a marketed ADC for lymphoma.	Talk Wed Nov 18 10–10:20am Part of Session 11: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 1 Clinical Relevance of ADC Immunogenicity: Are We Measuring What Matters? Immunogenicity · New modalities
BioNTech Mainz, Germany
biontech.com Biotech Develops mRNA vaccines and immunotherapies, including the COVID-19 vaccine developed with Pfizer, and cancer treatments.	Talk Thu Nov 19 12:30–12:50pm Part of Session 19: ADC Bioanalysis, From Community Recommendations to Complex PK Decisions Trust, but Verify: A Risk-Based Framework for Orthogonal LC-MS Investigation of Unexpected ADC Pharmacokinetic Profiles New modalities · LC–MS
Novo Nordisk Bagsværd, Denmark
novonordisk.com Pharma Pharmaceutical company focused on diabetes, obesity and rare blood and endocrine diseases, including GLP-1 medicines.	Talk Tue Nov 17 2–2:20pm Part of Session 5: Expanding LC–MS Bioanalysis: New Modalities, Advanced Workflows and Multi-Omics Beyond Plasma PK: Fit-for-Purpose Bioanalysis for Next-Generation siRNA and ASO Therapeutics New modalities · LC–MS